Roche Holding stock
ROP.SWSIXRoche Holding AG, HealthcareISIN CH1499059983
77Score 77 out of 100, Strong
Price and trend
80 / 100
Price history
+40% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is at its 52-week high. Largest decline in 20 years: 51% (January 2007 to August 2011).
Chart figures for advanced users
- SMA 50$448.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$417.32
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$336.08
- The lowest closing price of the last twelve months.
- Resistance$489.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Roche Holding AG belongs to the Drug Manufacturers (General) industry (Switzerland) and, with a market value of $396.4B, is number 4 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $74.13B (down 1.4% year on year) and earnings of $15.52B (up 55.6%).
- For fiscal 2026, analysts expect on average revenue of $76.37B (up 3%) and adjusted earnings per share of $24.65 (up 5.1%).
Show more
- MEQIRI Score 77 out of 100 (Strong): rank 44 of 714 in Healthcare, median 53.
- The P/E is 26.7 (Drug Manufacturers (General) median 25.6, own median of recent years 20.1).
- Our model puts fair value at $596.58, with the price 19% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 30 years.Capital allocation 80
- High return on capitalReturn on invested capital 28.3% in fiscal 2025, Drug Manufacturers (General) median 13.4%.Profitability 93
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 99
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and momentum, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- very large company
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $497.15 and expensive above $745.72 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $721.99 (cash-flow model) and $471.16 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $532.49, at 4.6% it would be $693.05.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 2.6% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating 31%, net 21%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 29 Jan 2026EPS reported $10.10 (expected $10.34)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $24.65+0.3%
- Revenue
- $76.37B+0.4%
- Earnings per share
- $26.640.0%
- Revenue
- $80.16B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: +6.8%HER2 franchise growth outlook raised to mid single digit from low single digit and the loss of exclusivity impact reduced to roughly CHF 600 million, while another area is now expected only at the lower end of its range.
“So also the reason why we updated our outlook for the full year or our additional information for the year and said we expect to lose roughly CHF 600 million due to loss of exclusivity.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Roche Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 77
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Eli LillyLLY $1.35T85
- Johnson & JohnsonJNJ $675.03B75
- AbbVieABBV $521.41B75
- MerckMRK $362.86B68
- NovartisNOVN.SW $302.09B76
- AstraZenecaAZN $287.66B73
- AmgenAMGN $253.21B77
- Gilead SciencesGILD $210.52B58
ETFs that hold Roche Holding
Held by 123 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Switzerland UCITS ETF 1DDBXS | 18.27% | 0.30% | €2.88B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 16.92% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 16.89% | 0.18% | €954.9M |
Show 5 more
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 16.85% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 16.11% | 0.46% | €729.65M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 10.10% | 0.25% | €237.76M |
| Xtrackers SLI UCITS ETF 1DDXS0 | 9.40% | 0.25% | €581.42M |
| iShares STOXX Europe 600 Top 20 UCITS ETF (DE)EXW3 | 7.43% | 0.20% | €141.47M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.